Charles Schwab Investment Management Inc. Raises Stock Holdings in Doximity, Inc. $DOCS

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Doximity, Inc. by 1.1% in the first quarter, holding approximately 786,914 shares valued at $45.67 million.
• Research firms have varied ratings for Doximity, with a target price range of $50 to $80, reflecting a mix of neutral, buy, and outperform ratings by different analysts.
• Insider selling was reported with two directors selling 10,000 shares each at an average price of $60, leading to notable decreases in their ownership percentages.

Charles Schwab Investment Management Inc. increased its holdings in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 1.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 786,914 shares of the company's stock after acquiring an additional 8,390 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.42% of Doximity worth $45,665,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. VSM Wealth Advisory LLC purchased a new stake in Doximity in the first quarter worth $29,000. Allworth Financial LP lifted its stake in Doximity by 104.0% in the first quarter. Allworth Financial LP now owns 563 shares of the company's stock worth $32,000 after acquiring an additional 287 shares during the period. Spire Wealth Management lifted its stake in Doximity by 73.2% in the first quarter. Spire Wealth Management now owns 615 shares of the company's stock worth $36,000 after acquiring an additional 260 shares during the period. Kapitalo Investimentos Ltda purchased a new position in Doximity during the fourth quarter valued at $50,000. Finally, Cullen Frost Bankers Inc. purchased a new position in Doximity during the first quarter valued at $64,000. Hedge funds and other institutional investors own 87.19% of the company's stock.

Doximity Price Performance

NASDAQ DOCS traded down $2.3550 during trading hours on Tuesday, hitting $63.5750. The company's stock had a trading volume of 1,165,300 shares, compared to its average volume of 2,338,769. The company's 50 day simple moving average is $60.18 and its two-hundred day simple moving average is $60.32. The company has a market cap of $11.91 billion, a P/E ratio of 63.58, a price-to-earnings-growth ratio of 4.10 and a beta of 1.36. Doximity, Inc. has a 12 month low of $35.32 and a 12 month high of $85.21.

Doximity (NASDAQ:DOCS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.05. Doximity had a return on equity of 21.75% and a net margin of 36.60%.The company's quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.28 earnings per share. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. As a group, research analysts predict that Doximity, Inc. will post 0.99 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Regina M. Benjamin sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the director directly owned 16,618 shares of the company's stock, valued at approximately $997,080. The trade was a 37.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Timothy S. Cabral sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the completion of the transaction, the director directly owned 6,360 shares in the company, valued at approximately $381,600. This represents a 61.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,000 shares of company stock valued at $2,140,940 in the last ninety days. Corporate insiders own 31.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on DOCS shares. BTIG Research raised Doximity from a "neutral" rating to a "buy" rating and set a $80.00 price objective for the company in a research report on Monday, June 2nd. Bank of America raised their price objective on Doximity from $55.00 to $62.00 and gave the company a "neutral" rating in a research report on Wednesday, June 25th. Mizuho lowered their price objective on Doximity from $65.00 to $60.00 and set a "neutral" rating for the company in a research report on Friday, May 16th. Canaccord Genuity Group raised their price objective on Doximity from $50.00 to $59.00 and gave the company a "hold" rating in a research report on Friday, August 8th. Finally, Needham & Company LLC lifted their price target on Doximity from $67.00 to $75.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $66.21.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.